Posted by Michael Wonder on 05 Aug 2021
New drug application for penpulimab monoclonal antibody (PD-1) for third-line treatment of metastatic nasopharyngeal carcinoma accepted by NMPA
5 August 2021 - Akeso announced that the new drug application of penpulimab (AK105) for third-line treatment of metastatic nasopharyngeal carcinoma, had been submitted and was accepted by the National Medical Products Administration of China.
This is the fourth indication of penpulimab of which the new drug application was successfully submitted in China and the United States.
Penpulimab is a new PD-1 monoclonal antibody that applies the immunoglobulin G1 subtype, modified by fragment crystallisable segment, which has a slower antigen binding off-rate.
